Nexalin Technology (NXL) Cash from Operations Growth (3y) (2024 - 2026)
Powered by 
Analysis
Nexalin Technology (NXL) Cash from Operations Growth (3y) (2024 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 179.79 Bn | 174.18 Bn | 7.27 Bn | 27.41% |
| 2 | Intuitive Surgical | 127.69 Bn | 122.47 Bn | 1.96 Bn | 16.81% |
| 3 | Medtronic | 117.23 Bn | 108.41 Bn | 6.34 Bn | 27.02% |
| 4 | Stryker | 103.55 Bn | 100.07 Bn | 4.50 Bn | 22.38% |
| 5 | Boston Scientific | 63.24 Bn | 62.70 Bn | 3.85 Bn | 30.85% |
| 6 | Edwards Lifesciences | 49.97 Bn | 45.72 Bn | 1.35 Bn | 168.71% |
| 7 | Alcon | 32.83 Bn | 31.37 Bn | 1.68 Bn | 16.21% |
| 8 | Dexcom | 32.30 Bn | 30.35 Bn | 830.00 Mn | 12.26% |
| 9 | Steris | 20.73 Bn | 20.25 Bn | 684.20 Mn | 9.30% |
| 10 | Nexalin Technology | 3.44 Mn | 2.44 Mn | 8,897.00 | -30.23% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -30.23% |
| Mar 31, 2026 | -9.22% |
| Dec 31, 2025 | -8.19% |
| Sep 30, 2025 | -15.82% |
| Jun 30, 2025 | -78.13% |
| Mar 31, 2025 | -91.44% |
| Dec 31, 2024 | -40.49% |